Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior    INDV   GB00BRS65X63

INDIVIOR

(INDV)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Indivior : loses U.S. district court battle, copycat launches imminent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 02:29am EDT

(Reuters) - Generic competitors to British drugmaker Indivior Plc's blockbuster opioid addiction treatment are on course to launch sales next week after the firm's attempt to stay a U.S. District court judgement was rejected.

The company said on Tuesday it would file a repeat motion to the Supreme Court, after having said last week that it faces rapid losses in market share "in the immediate future" to generic versions of Suboxone.

Earlier this month, a mandate by the U.S. Court of Appeals for the Federal Circuit opened the gates to rivals including India's Dr. Reddy's.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LTD -0.92% 2799.1 End-of-day quote.7.97%
INDIVIOR 2.32% 41 Delayed Quote.-64.33%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INDIVIOR
04/16INDIVIOR : US charges drugmaker Indivior, Reckitt over opioid healthcare fraud
AQ
04/15LONDON STOCK EXCHANGE : London's FTSE 100 subdued, IWG lifts midcaps
RE
04/11LONDON STOCK EXCHANGE : Brexit delay lifts mid-caps to six-month high; growth fe..
RE
04/11INDIVIOR : RB Group Plc - US Justice Department indictment of Indivior Plc
AQ
04/11INDIVIOR : Virginia drug company charged in billion-dollar opioid marketing frau..
AQ
04/11Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptio..
RE
04/11Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptio..
RE
04/11U.K. Drugmaker Charged -- WSJ
DJ
04/11INDIVIOR : shares collapse after US fraud indictment
AQ
04/11INDIVIOR : FTSE 100 inches lower as Indivior share price tanks
AQ
More news
Financials ($)
Sales 2019 454 M
EBIT 2019 20,0 M
Net income 2019 -12,0 M
Finance 2019 115 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 7,26
EV / Sales 2019 0,59x
EV / Sales 2020 0,53x
Capitalization 382 M
Chart INDIVIOR
Duration : Period :
Indivior Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIVIOR
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 1,77 $
Spread / Average Target 238%
EPS Revisions
Managers
NameTitle
Shaun Thaxter Chief Executive Officer & Executive Director
Howard H. Pien Chairman
Mark Crossley Chief Financial Officer & Executive Director
Christian Heidbreder Chief Scientific Officer
Ingo Elfering Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
INDIVIOR-64.33%382
WUXI APPTEC CO LTD25.49%16 286
MERCK KGAA6.58%13 863
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD36.27%10 651
KYOWA HAKKO KIRIN CO LTD3.70%10 145
JAZZ PHARMACEUTICALS PLC3.00%7 285